Cardiovascular Research

 
Stock Quotes for Cardiovascular Research top ^
  • Industry: Medical Devices
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for csii investment picks
  • Industry: Medical Devices
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for csii investment picks

 
News Articles for Cardiovascular Research top ^
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021800-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/15/11G021800/amarin-1279518830220.jpg BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 16, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study.
Sign-up for Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study investment picks
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), unveiled new data about the treatment of arterial calcification at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington D.C. Arterial calcium is a common occurrence for the millions of patients suffering from peripheral artery disease (PAD) and it can lead to significant complications.
Sign-up for Cardiovascular Systems Releases New Peripheral Data at 2014 TCT Conference investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), announced that the first seven patients in Japan have been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) study.
Sign-up for Cardiovascular Systems Enrolls First Seven Patients in Japan for Coast Study investment picks
RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus Canada NewsWire Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain and CALGARY, AB , Sept.
Sign-up for RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus investment picks
Symposium Builds on Philips' Support for SAVE Study Examining Impact of Obstructive Sleep Apnea Treatment on Cardiovascular Disease ANDOVER, Mass.
Sign-up for Philips Furthers Dialogue and Research on Cardiovascular Disease and Sleep Apnea at ESC Congress 2014 investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) today announced that its chairman of the board, Glen D.
Sign-up for Cardiovascular Systems, Inc.’s Board Chair to Retire investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) will host a live webcast of its fiscal 2015 first-quarter conference call on Wednesday, October 29, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, President and Chief Executive Officer, and Larry Betterley, Chief Financial Officer, will discuss the company’s results for its fiscal first quarter ended September 30, 2014, and its financial outlook.
Sign-up for Cardiovascular Systems to Webcast Fiscal 2015 First-Quarter Earnings Conference Call Wednesday, October 29 investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today announced that it has received CE (Conformité Européenne) Mark for its Stealth 360º Orbital Atherectomy System (OAS). Stealth 360º is a percutaneous OAS that is indicated to treat patients who suffer from peripheral arterial disease (PAD). “Securing CE Mark for Stealth 360º greatly expands our market opportunity and is an important milestone toward benefiting patients in Europe suffering from PAD—especially those with critical limb ischemia, (CLI) who have been underserved by other treatment options,” said David L.
Sign-up for Cardiovascular Systems Receives CE Mark for Stealth 360® Peripheral Orbital Atherectomy System investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal first quarter ended September 30, 2014.
Sign-up for Cardiovascular Systems Reports Fiscal 2015 First-Quarter Financial Results investment picks
Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain and CALGARY, AB , Sept.
Sign-up for RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus investment picks
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease.
Sign-up for Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers investment picks
2014/8/30
- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) - On all-cause mortality, LCZ696 doubled the effect that enalapril, an ACE-inhibitor, previously showed vs.
Sign-up for Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Cardiovascular Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Cardinal Health  |  Next: Care Bond Funds